Many other clinical studies also have confirmed that SGLT2 inhibitors are widely used to treat HF patients due to their clinical benefits.[16] There are several potential mechanisms about how SGLT2 inhibitors may reduce LV dilation and improve cardiac function for patients with HF and DCM. The gene discussed is SLC5A2; the disease is familial dilated cardiomyopathy.